Angiotensin-converting enzyme 2 amplification limited to the circulation does not protect mice from development of diabetic nephropathy

Kidney International

Volumn 91, Issue 6, 2017, Pages 1336-1346

  Wysocki, Jan ^a   Ye, Minghao ^a   Khattab, Ahmed M ^a   Fogo, Agnes ^b   Martin, Aline ^a   David, Nicolae Valentin ^a   Kanwar, Yashpal ^a   Osborn, Mark ^c   Batlle, Daniel ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

angiotensin 1 7; angiotensin II; diabetic nephropathy; minicircle delivery; soluble ACE2

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; MINICIRCLE DNA; ANGIOTENSIN I; ANGIOTENSIN I (1-7); AUTOANTIGEN; COLLAGEN TYPE 4; DIPEPTIDYL CARBOXYPEPTIDASE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN; TYPE IV COLLAGEN ALPHA3 CHAIN;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; GLOMERULAR CELLULARITY; GLOMERULAR SIZE; GLOMERULUS FILTRATION RATE; KIDNEY HYPERTROPHY; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; SERUM; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; BLOOD; C57BL MOUSE; COMPLICATION; DEFICIENCY; ENZYMOLOGY; EXPERIMENTAL DIABETES MELLITUS; FEMALE; GENETICS; KIDNEY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TIME FACTOR;

ALBUMINURIA; ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; AUTOANTIGENS; COLLAGEN TYPE IV; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; KIDNEY; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 85008393970     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2016.09.032     Document Type: Article

References (69)

1. Raij, L., The pathophysiologic basis for blocking the renin-angiotensin system in hypertensive patients with renal disease. Am J Hypertens 18 (2005), 95S–99S.
2. Gurley, S.B., Coffman, T.M., The renin-angiotensin system and diabetic nephropathy. Semin Nephrol 27 (2007), 144–152.
3. de Zeeuw, D., Remuzzi, G., Parving, H.H., et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110 (2004), 921–927.
4. Bichu, P., Nistala, R., Khan, A., et al. Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. Vasc Health Risk Manag 5 (2009), 129–140.
5. Brenner, B.M., Cooper, M.E., de Zeeuw, D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001), 861–869.
6. Remuzzi, G., Ruggenenti, P., Perna, A., et al. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J Am Soc Nephrol 15 (2004), 3117–3125.
7. Batlle, D., Wysocki, J., Soler, M.J., et al. Angiotensin-converting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy. Kidney Int 81 (2012), 520–528.
8. Wysocki, J., Ye, M., Rodriguez, E., et al. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension 55 (2010), 90–98.
9. Dilauro, M., Burns, K.D., Angiotensin-(1-7) and its effects in the kidney. Scientific World Journal 9 (2009), 522–535.
10. Zimmerman, D.L., Zimpelmann, J., Xiao, F., et al. The effect of angiotensin-(1-7) in mouse unilateral ureteral obstruction. Am J Pathol 185 (2015), 729–740.
11. Li, N., Zimpelmann, J., Cheng, K., et al. The role of angiotensin converting enzyme 2 in the generation of angiotensin 1-7 by rat proximal tubules. Am J Physiol Renal Physiol 288 (2005), F353–F362.
12. Ye, M., Wysocki, J., Naaz, P., et al. Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination?. Hypertension 43 (2004), 1120–1125.
13. Pinheiro, S.V., Ferreira, A.J., Kitten, G.T., et al. Genetic deletion of the angiotensin-(1-7) receptor Mas leads to glomerular hyperfiltration and microalbuminuria. Kidney Int 75 (2009), 1184–1193.
14. Moon, J.Y., Tanimoto, M., Gohda, T., et al. Attenuating effect of angiotensin-(1-7) on angiotensin II-mediated NAD(P)H oxidase activation in type 2 diabetic nephropathy of KK-A(y)/Ta mice. Am J Physiol Renal Physiol 300 (2011), F1271–F1282.
15. Benter, I.F., Yousif, M.H., Dhaunsi, G.S., et al. Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am J Nephrol 28 (2008), 25–33.
16. Varagic, J., Ahmad, S., Nagata, S., et al. ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury. Curr Hypertens Rep, 16, 2014, 420.
17. Giani, J.F., Burghi, V., Veiras, L.C., et al. Angiotensin-(1-7) attenuates diabetic nephropathy in Zucker diabetic fatty rats. Am J Physiol Renal Physiol 302 (2012), F1606–F1615.
18. Mori, J., Patel, V.B., Ramprasath, T., et al. Angiotensin 1-7 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation, and lipotoxicity. Am J Physiol Renal Physiol 306 (2014), F812–F821.
19. Tikellis, C., Bialkowski, K., Pete, J., et al. ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes 57 (2008), 1018–1025.
20. Yamaleyeva, L.M., Gilliam-Davis, S., Almeida, I., et al. Differential regulation of circulating and renal ACE2 and ACE in hypertensive mRen2.Lewis rats with early-onset diabetes. Am J Physiol Renal Physiol 302 (2012), F1374–F1384.
21. Wysocki, J., Garcia-Halpin, L., Ye, M., et al. Regulation of urinary ACE2 in diabetic mice. Am J Physiol Renal Physiol 305 (2013), F600–F611.
22. Roberts, M.A., Velkoska, E., Ierino, F.L., et al. Angiotensin-converting enzyme 2 activity in patients with chronic kidney disease. Nephrol Dial Transplant 28 (2013), 2287–2294.
23. Soro-Paavonen, A., Gordin, D., Forsblom, C., et al. Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. J Hypertens 30 (2012), 375–383.
24. Donoghue, M., Hsieh, F., Baronas, E., et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87 (2000), E1–E9.
25. Lew, R.A., Warner, F.J., Hanchapola, I., et al. Characterization of angiotensin converting enzyme-2 (ACE2) in human urine. Int J Pept Res Ther 12 (2006), 283–289.
26. Nadarajah, R., Milagres, R., Dilauro, M., et al. Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice. Kidney Int 82 (2012), 292–303.
27. Lambert, D.W., Yarski, M., Warner, F.J., et al. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem 280 (2005), 30113–30119.
28. Tipnis, S.R., Hooper, N.M., Hyde, R., et al. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275 (2000), 33238–33243.
29. Rice, G.I., Jones, A.L., Grant, P.J., et al. Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. Hypertension 48 (2006), 914–920.
30. Levy, A., Yagil, Y., Bursztyn, M., et al. ACE2 expression and activity are enhanced during pregnancy. Am J Physiol Regul Integr Comp Physiol 295 (2008), R1953–R1961.
31. Kawajiri, M., Mogi, M., Higaki, N., et al. Angiotensin-converting enzyme (ACE) and ACE2 levels in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler 15 (2009), 262–265.
32. Marshall, A.C., Shaltout, H.A., Pirro, N.T., et al. Antenatal betamethasone exposure is associated with lower ANG-(1–7) and increased ACE in the CSF of adult sheep. Am J Physiol Regul Integr Comp Physiol 305 (2013), R679–R688.
33. Chappell, M.C., Of diabetic mice and ACE2: a new biomarker of renal disease?. Am J Physiol Renal Physiol 305 (2013), F970–F972.
34. Soler, M.J., Wysocki, J., Ye, M., et al. ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. Kidney Int 72 (2007), 614–623.
35. Ye, M., Wysocki, J., William, J., et al. Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol 17 (2006), 3067–3075.
36. Oudit, G.Y., Liu, G.C., Zhong, J., et al. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 59 (2010), 529–538.
37. Ye, M., Wysocki, J., Gonzalez-Pacheco, F.R., et al. Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2. Hypertension 60 (2012), 730–740.
38. Chen, Z.Y., He, C.Y., Ehrhardt, A., et al. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther 8 (2003), 495–500.
39. Osborn, M.J., McElmurry, R.T., Lees, C.J., et al. Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of alpha-L-iduronidase in mice with mucopolysaccharidosis type I. Mol Ther 19 (2011), 450–460.
40. Cosgrove, D., Meehan, D.T., Grunkemeyer, J.A., et al. Collagen COL4A3 knockout: a mouse model for autosomal Alport syndrome. Genes Dev 10 (1996), 2981–2992.
41. Tanaka, M., Asada, M., Higashi, A.Y., et al. Loss of the BMP antagonist USAG-1 ameliorates disease in a mouse model of the progressive hereditary kidney disease Alport syndrome. J Clin Invest 120 (2010), 768–777.
42. Gross, O., Beirowski, B., Koepke, M.L., et al. Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int 63 (2003), 438–446.
43. Juillerat, L., Nussberger, J., Menard, J., et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 16 (1990), 564–572.
44. Campbell, D.J., Alexiou, T., Xiao, H.D., et al. Effect of reduced angiotensin-converting enzyme gene expression and angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptide levels in mice. Hypertension 43 (2004), 854–859.
45. van Kats, J.P., Duncker, D.J., Haitsma, D.B., et al. Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin II. Circulation 102 (2000), 1556–1563.
46. Tikellis, C., Brown, R., Head, G.A., et al. Angiotensin-converting enzyme 2 mediates hyperfiltration associated with diabetes. Am J Physiol Renal Physiol 306 (2014), F773–F780.
47. Katoh, M., Ohmachi, Y., Kurosawa, Y., et al. Effects of imidapril and captopril on streptozotocin-induced diabetic nephropathy in mice. Eur J Pharmacol 398 (2000), 381–387.
48. Candido, R., Allen, T.J., Lassila, M., et al. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation 109 (2004), 1536–1542.
49. Dietz, W.M., Skinner, N.E., Hamilton, S.E., et al. Minicircle DNA is superior to plasmid DNA in eliciting antigen-specific CD8+ T-cell responses. Mol Ther 21 (2013), 1526–1535.
50. Viecelli, H.M., Harbottle, R.P., Wong, S.P., et al. Treatment of phenylketonuria using minicircle-based naked-DNA gene transfer to murine liver. Hepatology 60 (2014), 1035–1043.
51. Gurley, S.B., Clare, S.E., Snow, K.P., et al. Impact of genetic background on nephropathy in diabetic mice. Am J Physiol Renal Physiol 290 (2006), F214–F222.
52. Brosius, F.C. 3rd, Alpers, C.E., Bottinger, E.P., et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol 20 (2009), 2503–2512.
53. Gurley, S.B., Mach, C.L., Stegbauer, J., et al. Influence of genetic background on albuminuria and kidney injury in Ins2(+/C96Y) (Akita) mice. Am J Physiol Renal Physiol 298 (2010), F788–F795.
54. Chang, J.H., Paik, S.Y., Mao, L., et al. Diabetic kidney disease in FVB/NJ Akita mice: temporal pattern of kidney injury and urinary nephrin excretion. PLoS One, 7, 2012, e33942.
55. Chang, J.H., Gurley, S.B., Assessment of diabetic nephropathy in the Akita mouse. Methods Mol Biol 933 (2012), 17–29.
56. Zheng, S., Noonan, W.T., Metreveli, N.S., et al. Development of late-stage diabetic nephropathy in OVE26 diabetic mice. Diabetes 53 (2004), 3248–3257.
57. Hudkins, K.L., Pichaiwong, W., Wietecha, T., et al. BTBR Ob/Ob mutant mice model progressive diabetic nephropathy. J Am Soc Nephrol 21 (2010), 1533–1542.
58. Price, D.A., Porter, L.E., Gordon, M., et al. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 10 (1999), 2382–2391.
59. Hollenberg, N.K., Direct renin inhibition and the kidney. Nat Rev Nephrol 6 (2010), 49–55.
60. Anderson, S., Role of local and systemic angiotensin in diabetic renal disease. Kidney Int Suppl 63 (1997), S107–S110.
61. Fisher, N.D., Price, D.A., Litchfield, W.R., et al. Renal response to captopril reflects state of local renin system in healthy humans. Kidney Int 56 (1999), 635–641.
62. Velez, J.C., The importance of the intrarenal renin-angiotensin system. Nat Clin Pract Nephrol 5 (2009), 89–100.
63. Schlueter, W., Keilani, T., Batlle, D.C., Tissue renin angiotensin systems: theoretical implications for the development of hyperkalemia using angiotensin-converting enzyme inhibitors. Am J Med Sci 307:suppl 1 (1994), S81–S86.
64. Iyer, S.N., Chappell, M.C., Brosnihan, K.B., et al. Role of AT1 and AT2 receptors in the plasma clearance of angiotensin II. J Cardiovasc Pharmacol 31 (1998), 464–469.
65. Yamada, K., Iyer, S.N., Chappell, M.C., et al. Converting enzyme determines plasma clearance of angiotensin-(1-7). Hypertension 32 (1998), 496–502.
66. Wysocki, J., Ye, M., Batlle, D., Plasma and kidney angiotensin peptides: importance of the aminopeptidase A/angiotensin III axis. Am J Hypertens 28 (2015), 1418–1426.
67. Wysocki, J., Ye, M., Soler, M.J., et al. ACE and ACE2 activity in diabetic mice. Diabetes 55 (2006), 2132–2139.
68. Haber, P.K., Ye, M., Wysocki, J., et al. Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators: studies in vivo, ex vivo, and in vitro. Hypertension 63 (2014), 774–782.
69. Matsusaka, T., Niimura, F., Pastan, I., et al. Podocyte injury enhances filtration of liver-derived angiotensinogen and renal angiotensin II generation. Kidney Int 85 (2014), 1068–1077.